Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Receivables (2016 - 2025)

Adma Biologics (ADMA) has disclosed Change in Receivables for 13 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 14820.57% year-over-year to $20.8 million, compared with a TTM value of $108.4 million through Dec 2025, up 380.25%, and an annual FY2025 reading of $108.4 million, up 380.25% over the prior year.
  • Change in Receivables was $20.8 million for Q4 2025 at Adma Biologics, down from $27.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $49.4 million in Q1 2025 and bottomed at -$19.5 million in Q2 2024.
  • Average Change in Receivables over 5 years is $7.3 million, with a median of $5.2 million recorded in 2021.
  • The sharpest move saw Change in Receivables crashed 1654.71% in 2021, then surged 14820.57% in 2025.
  • Year by year, Change in Receivables stood at $8.2 million in 2021, then tumbled by 165.95% to -$5.4 million in 2022, then grew by 27.78% to -$3.9 million in 2023, then surged by 96.38% to -$141000.0 in 2024, then soared by 14820.57% to $20.8 million in 2025.
  • Business Quant data shows Change in Receivables for ADMA at $20.8 million in Q4 2025, $27.9 million in Q3 2025, and $10.3 million in Q2 2025.